Paris Cancer Institute: CARPEM has a strong activity in uro-oncology and involves 3 departments of APHP.Centre (Hematology and Oncology department, Imaging, Nuclear Medicine and Pathology department and Biology, Physiology and Genomic Medicine department). It is the most important surgical center dedicated to uro-oncology tumor in the Great Paris with national and international expertise in prostate, bladder and kidney tumors. Specifically, 28 beds in urology are dedicated to uro-oncology. This program took in charge 2995 new cases of prostate, kidney, bladder cancers during the last 3 years (see table 2), 1339 new cases of urological tumors have been surgically removed during the last 3 years and 2415 cycles of chemotherapy/immunotherapy have been performed (for detail see annex 1). It involves 2 sites of the APHP.Centre (Pompidou and Cochin hospitals) with very similar organization with both medical and surgery strengths. Furthermore, a dedicated genetic counselling is proposed for patients in case of suspicion of Von Hippel Lindau disease, Birt-Hogg-Dubé syndrome, etc…. One hundred patients and their relatives are addressed to this consultation each year for suspicion of hereditary renal cancers. All these clinical activities are structured around 2 weekly cancer multidisciplinary team meetings. These meetings follow the INCA national guidelines, and ESMO guidelines.
This program developed intensive clinical and translational research in broad fields from surgery to personalized medicine. A strong expertise in the clinical care of metastatic kidney disease from surgery to immunotherapy has been acquired during last years. A first trial based on genomic characterization of kidney cancers has been launched (BIONIKK trial). The program developed also an expertise in robotic prostatic surgery and on focal treatment modalities as well as in personalized medicine and immunotherapy in bladder cancer.
Clinical research is developed according to 2 axes (clinical interventional trial and surgery) with strong commitment of both medical physicians and surgeons. In the following section we will highlight the major successes in medical and surgical innovation in treatment of urologic cancers of 2018. In a nutshell 37 clinical trials are open to inclusion (22 phase III, 15 phase Ib/II) see annex 2. Twelve are dedicated to prostate cancer, 14 are dedicated to bladder cancer and 11 are dedicated to renal cancer.
Recent studies on chemotherapy and new hormonal therapies in prostate cancers were conducted and have shown the lack of treatment efficacy of hormonal therapy combo or alone or with docetaxel in patients with rising PSA and hormone sensitive (Oudard S et al, JAMA Oncol 2019). We also led a large European retrospective study based on CATS registry showing that clinical progression in metastatic castration-resistant prostate cancer patients is associated with poor outcomes as compared to prostate-specific antigen or radiological only progression (Delanoy N et al, Eur J Cancer 2019). We participated to the phase 3 SPARTAN trial to evaluate the effect of apalutamide on metastasis-free survival in nonmetastatic castration-resistant prostate cancer and a PSA doubling time of 10 months or less showing metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo (Smith MR et al, New Engl J Med 2018).
Concerning surgery, we focused our research on focal treatment modalities. Prof. N. Barry Delongchamps set up the FOSTINE trial (NCT03023345) which is a “first-in-man” pilot study evaluating microwave focal ablation, delivered through a trans-rectal approach, with organ-based tracking image fusion. The main endpoint was reached in 8 among the 10 patients already treated (80%) with no reported adverse event after one-year follow-up. A multicentric European trial coordinated by Prof. N. Barry Delongchamps, will start in December 2019. Primary endpoint will be the absence of tumor within the treated area at 1 year.
Renal, Urothelial and Bladder cancers
Pr. A Mejean led an international phase III trial in metastatic renal carcinoma demonstrating the non-inferiority of the sunitinib arm as compared to the nephrectomy-sunitinib arm with regard to overall survival. No significant differences in response rate or progression-free survival was observed (Méjean A et al, New Engl J Med 2018).
Set-up by our group, we are conducting 2 phase II trials : BIONIKK trial (NCT02960906) first gene expression based randomized phase II trial in renal cell carcinoma (see research translational section), and NEMIO phase II trial (NCT03549715) testing the combination of chemotherapy with immune checkpoint blocker (ICB) in muscle invasive bladder cancer in neoadjuvant setting (see figure). The first 12 patients have been enrolled from December 2018 and July 2019 and we expect recruitment to be completed in 2021.
Our translational research is based both on the characterization of genetic alterations in tumors cells and on the study of tumor microenvironment (immune and endothelial cells). This programinvolves 4 research teams of the SIRIC CARPEM. These research teams are led by E. Tartour, AP. Roqueplo, I. Cremer, and J. Zucman-Rossi. A collaboration was set-up with V.Coffin team at the INEM.
Microenvironment and genomics in clear-cell Renal Cell Carcinoma RCC
One of the major achievements in the last 5 years is the molecular characterization of the tumor cells and their microenvironment in kidney cancer. A significant contribution has been done to the molecular transcriptomic analysis of RCC within the “Programme Carte d’Identité des Tumeurs” leading by the French League Against Cancer. Based on these characterizations, 4 different RCC groups were identified. These results lead us to set-up the first gene expression based randomized phase II trial in RCC, BIONIKK-1 trial (NCT02960906) testing either tyrosine kinase inhibitors or ICB according to the determination of molecular metastatic RCC subgroups. Two hundred patients were randomized, the last being in July 2019.
We participated to TRACERx Renal program, using combination of whole-genome sequencing analysis and multi-region sampling approach to provide insights into the nature and key oncogenic events in RCC (Mitchell TJ et al, Cell 2018).
Pr. Helley and Dr. Mauge (E. Tartour team at PARCC) conduct a translational program that focuses on the study of the circulating vascular compartment including mature or progenitor circulating endothelial cells, and plasma factors related to angiogenesis. They assessed the role of plasma biomarkers to predict the response to antiangiogenic treatments in 2 clinical trials including patients with renal and prostate cancer. They showed in PREINSUT phase II trial (NCT00930345) that biomarkers associated with primary renal tumor size change under sunitinib treatment were stromal cell-derived factor-1 (SDF1) and platelet-derived growth factor (PDGF) (Mauge L et al, Clin Cancer Res 2018).
Dr Burnichon, Dr Favier, Dr Verkarre and Pr Timsit (J Favier & AP Roqueplo Team) are developing a program dedicated to rare RCC. Based on their former studies on integrative genomic characterization of pheochromocytoma and paraganglioma that led to the identification of new therapeutic targets and biomarkers (Job S, Clin Cancer Res, 2019), they built a program dedicated to the molecular profiling of rare subtypes of kidney tumors. Their main objective is the identification of carcinogenesis pathways involved in the different rare RCC subtypes and their relevance for targeted therapy. Chromophobe RCCs are currently extensively studied.
Based on 2 different studies PREINSUT and BIONIKK, Pr. L. Fournier (B. Tavitian team) developed a radiomics approach in RCC. A radiomic signature that differentiated two groups of patients with very different outcomes in terms of PFS (1.4 vs. 16.1 months, p = 0.0075) and OS (5.6 vs 29.2 months; p = 1.78.10-5) was identified. Confirmation of these results is being analyzed on an independent validation population from the BIONIKK study.
Stem cell studies in prostate cancers
The team of V. Goffin uses various preclinical models and clinical samples to understand the molecular and cellular bases of prostate cancer resistance to castration. The team recently identified stem/progenitor cells that resist castration and promote cancer recurrence. Current researches aim to identify clinically relevant biomarkers of these castration-resistant primitive cells and actionable pathways to eradicate them.
All these research areas are developed in programs 1 and 2 of the SIRIC CARPEM.
The Urologic cancer Program integrates 20 residents and 18 fellows each year. Weekly dedicated internal seminars are organized on both sites.
Medical and surgical teams are widely involved in the university teaching of urologic pathologies in University of Paris and in several national teaching degrees/master’s degrees in the field of oncology :
Based on our skillness we would like to
|Name||Title||Speciality||Clinical/Research Unit||Resarch Team / Hospital|
|Stphane Oudard||Full Prof||Oncologist||PARCC U970||Immunotherapy and anti-angiogenic therapy in oncology|
|Arnaud Mejean||Full Prof||Surgeon||Departmenf of Urology||HEGP hospital|
|Michael Peyromaure||Full Prof||Surgeon||Departmenf of Urology||Cochin hospital|
|Jrme Alexandre||Full Prof||Oncologist||UMRS 1138||Cordeliers Personalized medecine therapeutic optimization|
|Nicolas Barry de Longchamps||Full Prof||Surgeon||U1151||PRL/GH Pathophysiology|
|Eric Tartour||Full physician||Immunologist||PARCC U970||Personalized medecine therapeutic optimization|
|Marc Olivier Timsit||Full Prof||Surgeon||PARCC U970||Genetics and Metabolism of Rare Cancers|
|Laure Fournier||Full Prof||Radiologist||INSERM UMR-S970||Cardiovascular Research Center|
|Virginie Verkarre||Full time physician||Pathologist||PARCC U970||Genetics and Metabolism of Rare Cancers|
|Sibony Mathilde||Full Prof||Pathologist|
|Anne Paule Gimenez||Full Prof||Genetic||PARCC U970||Equipe Gntique et Mtabolisme des cancers rares|
|Sarah Kreps||Full time physician||Radiation therapist||INSERM UMR 1138 Team 22||Information Sciences to support Personalized Medicine,|
|Francois Goldwasser||Full Prof||Oncologist||EA 4466 PRETRAM, Pharmacy Faculty||CAncer Research for PErsonalized Medicine (CARPEM),|
|Benoit Blanchet||Full time physician||Pharmacologist||Inserm U1268, CiTCom UMR8038 CNRS,||Pharmacokinetics and Pharmacochemistry Unit|
|Jrme Galon||Full time physician||Biologist||Inserm U1138||Laboratory of Integrative Cancer Immunology|
|Jrme Batteux||Full time physician||Biologist||Inserm U1268, CiTCom UMR8038 CNRS,||Pharmacokinetics and Pharmacochemistry Unit|
|Jean Michel Correas||Full Prof||Radiologist||CNRS UMR 7587, INSERM ERL U-979,||Institut Langevin, ESPCI Paris, PSL Research University|
|Yann-Alexandre Vano||Full time physician||Oncologist||INSERM1138||Inflammation, complement and cancer,|
|Catherine Sautes Fridman||Full Prof||Immunologist||INSERM1138||Inflammation, complement and cancer team|
|Herv Fridman||Full Prof||Immunologist||INSERM1138||Inflammation, complement and cancer team|
|Olivier Huillard||Full time physician||Oncologist||EA 4466 PRETRAM, Pharmacy Faculty||CAncer Research for PErsonalized Medicine (CARPEM),|
|Francois Audenet||Full time physician||Surgeon||Departmenf of Urology||EGP hospital|
|Charles Dariane||Full Prof||Surgeon||Departmenf of Urology||EGP hospital|
|Vincent Goffin||Research Director Inserm||Basic Research||INEM U1151||PRL/GH Pathophysiology: Translational Approaches|
|Laetitia Mauge||Full time physician||Biologist||PARCC U970||Personalized medecine therapeutic optimization|
|Burnichon Nelly||Associated Prof||Molecular Genetics||PARCC U970||Genetics and Metabolism of Rare Cancers|
|Favier Judith||Research director||Biologist||PARCC U970||Genetics and Metabolism of Rare Cancers|
|Bastien Rance||Full Prof||Biomedical Informatics||INSERM 1138||Information science to support personalized medicine|
The selected following publications highlight the strength of clinical and translational research developed in the urologic program:
Number of new prostate cancer
Number of prostatectomy
Number of day-care treatments (chemotherapy)
Number of new kidneys cancers
Number of nephrectomies
Number of 1st line TKI or I-O in mKC
KC: Kidney cancer; TKi: Tyrosine kinase inhibitor
Number of new bladders cancers
Number of cystectomy
Number of 1st line CT or I-O in mBC
Number of new testicular cancer
Number of orchidectomy
Number of 1st line CT in mTC
|Organ||Sponsor Title||Phase||NCT number||Coordinator / Investigator|
|Kidney||PIVOTAL/ PT2977-202 An Open-Label Phase 2 Study to evaluate PT2977 for the Treatment of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma||II||NCT03401788||Dr S. RICHARD / Pr S. OUDARD|
|Kidney||Unicancer A phase II study assessing the safety of Nivolumab in patient with Metastatic Renal Carcinoma progressing during or after prior systemic anti-angiogenic therapy.( NIVOREN)||II||NCT03013335||Dr B.ESCUDIER / Pr S.OUDARD|
|Kidney||ARTIC A Phase II BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR TKI in Na夫e Metastatic Kidney Cancer (BIONIKK)||II||NCT02960906||Dr Y. VANO / Pr S.OUDARD|
|Kidney||Unicancer Secured access to nivolumab for adult patients with selected rare cancer types ( Cohort 1: Non clear cell RCC) (AcSE Nivolumab)||II||NCT03012581||Dr A.MARABELLE / Pr S. OUDARD|
|Kidney||CHRU BESANCON Open Label, Randomized Multi-center Phase II Study to Assess the Efficacy and Tolerability of Sunitinib by Dose Administration Regimen (Dose Modification or Dose Interruptions) in Patients With Advanced or Metastatic Renal Cell Carcinoma (SURF)||II||NCT02689167||Dr A.THIERY-VUILLEMIN / Dr Y.VANO|
|Kidney||BMS/ CA 209-214 A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (CHECKMATE 214)||III||NCT02231749||Dr B.ESCUDIER / Pr S.OUDARD|
|Kidney||BMS/ CA 209-025 A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy(CHECKMATE 025)||III||NCT01668784||Dr B.ESCUDIER / Pr S.OUDARD|
|Kidney||EXELIXIS/ XL184-308 A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy (METEOR)||III||NCT01865747||Dr B.ESCUDIER / Pr S.OUDARD|
|Kidney||MSD/ MK3475-564 A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)||III||NCT03142334||Pr S.OUDARD / Pr S.OUDARD|
|Kidney||MSD/ MK3475-426 A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)||III||NCT02853331||Pr C.LINASSIER / Pr S.OUDARD|
|Kidney||EISAI A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR).||III||NCT02811861||Pr S.OUDARD / Pr S.OUDARD|
|Prostate||APHP A phase II study assessing intra-individual dose escalation of abiraterone acetate based on plasma concentration in patients with castration resistant metastatic prostate cancer and tumor progression (OPTIMABI)||II||NCT03458247||Pr J. ALEXANDRE / Pr S.OUDARD|
|Prostate||MSD/MK 3475-365 Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)||Ib/II||NCT02861573||Dr G.GRAVIS / Pr S.OUDARD|
|Prostate||ARTIC Randomized multicenter, phase III trial evaluating the safety of 2 schedules of cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men (ｳ 65years) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen (CABASTY)||III||NCT02961257||Pr S.OUDARD / Pr S.OUDARD|
|Prostate||UNICANCER A phase 3 Randomized, placebo-controlled, Double blind Study of JNJ56021927 plus androgen Deprivation Therapy (ADT) versus ADT in subjects whit low volume Metastatic Hormone-sensitive Prostate Cancer (mHSPC)||III||NCT02489318||Pr M.O.TIMSIT / Dr C.THIBAULT|
|Prostate||JANSSEN/ 64091742PCR3001 A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer (MAGNITUDE)||III||NCT03748641||Dr A.THIERY-VUILLEMIN / Pr S.OUDARD|
|Prostate||SOTIO/ SP005 Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (VIABLE)||III||NCT02111577||Dr N. BARRY DELONGCHAMPS / Pr S.OUDARD|
|Prostate||PFIZER/ C3441021 A phase 3 randomized, double-blind, placebo-controlled study of talazoparib with enzalutamide in metastatic castration-resistant prostate cancer (TALAPRO-2)||III||NCT03395197||Pr K. FIZAZI / Pr S.OUDARD|
|Prostate||JANSSEN/ 56021927PCR3001: a phase III randomized, placebo controlled Double-blind Study of JNJ-56021927 in combination with Abiraterone Acetate and Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subject with Chemotherapy-na夫e Metastatic Castration-resistant Prostate Cancer(mCRPC) (ACIS)||III||NCT02257736||Pr S.OUDARD / Pr S.OUDARD|
|Prostate||MEDIVATION/ MDV3100-14: A Multinational, Phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study of Enzalutamide in patients with non metastatic castration-resistant prostate cancer (PROSPER)”||III||NCT02003924||Pr S.OUDARD / Pr S.OUDARD|
|Prostate||ARAGON Pharmaceuticals A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN_509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer (SPARTAN)||III||NCT01946204||Pr S.OUDARD / Pr S.OUDARD|
|Prostate||UNICANCER A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse (PEACE 2)||III||NCT01952223||Pr K. FIZAZI / Pr S.OUDARD|
|Prostate||SANOFI/ LPS14201 A randomized, open label, multicenter study of Cabazitaxel versus an Androgen Receptor (AR)-targeted agent (abiraterone or enzalutamide) in mCRPC patients previously treated with Docetaxel and who rapidly failed a prior AR-targeted agent (CARD)||IV||NCT02485691||Pr S.OUDARD / Pr S.OUDARD|
|Bladder||ARTIC Neoadjuvant dose-dense MVAC In combination with durvalumab (MEDI4736) and tremelimumab in muscle-invasive urothelial carcinoma (NEMIO)||I/II||NCT03549715||Pr S.OUDARD / Dr C.THIBAULT|
|Bladder||JANSSEN/ 427556493BLC2002 A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with Selected FGFR Gene Alterations (NORSE)||Ib/II||NCT03473743||Dr Y.LORIOT / Dr Y.VANO|
|Bladder||IGR A Phase II Study Evaluating Neoadjuvant pembrolizumab monotherapy in Patients with Muscle-Invasive Bladder Cancer to Explore in vivo the Mechanisms of Action of pembrolizumab (PANDORE)||II||NCT03212651||Dr Y. LORIOT / Dr C. THIBAULT|
|Bladder||NEKTAR Therapeutics/ NEKTAR 18-214-10 A Phase 2, randomized, non-comparative, open-label study of NKTR-214 in combination with nivolumab and of chemotherapy in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients with low PD-L1 expression (PIVOT-10)||II||NCT03785925||Dr Y. LORIOT / Dr C. THIBAULT|
|Bladder||CHU Bordeaux Gemcitabine Cisplatin plus Avelumab or Gemcitabine Cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma ( GSISAVE)||II||NCT03324282||Pr A. RAVAUD / Pr S.OUDARD|
|Bladder||BOEHRINGER INGELHEIM /BI “Phase II open label single arm exploratory trial of oral Afatinib immunotherapy following platinum failure for patients with advanced/metastatic urothelial tract carcinoma with with genetic alterations in ERBB receptors.LUX-Bladder1″” 1200.261:” genetic alterations in ERBB receptors.LUX-Bladder1″” 1200.261:”||II||NCT02780687||Dr. A. Font / Pr S.OUDARD, Dr HUILLARD|
|Bladder||IMMUNOMEDICS / TROPHY U-01 : A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy||II||NCT03547973||Dr HUILLARD|
|Bladder||JANSSEN/ 42756493BLC3001 A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (THOR)||III||NCT03390504||Dr Y. LORIOT / Dr Y. VANO|
|Bladder||BAYER / FORT-1: Phase 2/3 study of rogaratinib (BAY 1163877) vs chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma||II/III||NCT03410693||Dr HUILLARD|
|Bladder||ASTELLAS/ 7465-CL-0301 An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)||III||NCT03474107||Dr M. GROS-GOUPIL / Dr Y.VANO|
|Bladder||Unicancer An open label, randomized, phase III trial, evaluating efficacy of Atezolizumab in addition to one year BCG (Bacillus Calmette-Guerin) bladder instillation in BCG-naive patients with high-risk non-muscle invasive Bladder cancer (ALBAN)||III||NCT03799835||Pr M. ROUPRET / Dr C. THIBAULT- Dr HUILLARD|
|Bladder||ROCHE/ WO29636 A phase III, open-label, multicenter randomized study of atezolizumab ( anti-PDL1 antibody) versus observation as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma after surgical resection (IMvigor010)||III||NCT02450331||Pr S. OUDARD / Dr HUILLARD|
|Bladder||MSD/ MK 3475-905 Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-905)||III||NCT03924895||Pr S. OUDARD / Dr HUILLARD|
|Bladder||MSD /MK3475-361: Phase III study, randomized, controlled, evaluating pembrolizumab with or without a platinum-based CT versus CT alone in patient with advanced or metastatic urothelial carcinoma(KEYNOTE-361)||III||NCT02853305||Pr S. OUDARD / Dr HUILLARD|
Centre Universitaire des Saints-Pères Etage 4 – Pièce 446B 45 rue des Saints-Pères -75006 Paris
Carina Binet : Secrétaire Général du CARPEM
Tél. : 01 76 53 43 85 – firstname.lastname@example.org
Aurore Hattabi, PhD : Coordinatrice Scientifique du CARPEM
Tél : 01 76 53 43 85 – email@example.com